Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol

Biomedical and Environmental Sciences

Volumn 26, Issue 4, 2013, Pages 249-257

  Lin, Si En ^a   Huang, Jian Ping ^a   Wu, Ling Zhi ^a   Wu, Tie ^a   Cui, Liao ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Guangdong Key Laboratory for Research and Development of Natural Drugs   (China)

Author keywords

Aspirin; Diethylstilbestrol; Dyslipidemia; Osteoporosis; Ovariectomy; Rat

Indexed keywords

RATTUS;

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; DIETHYLSTILBESTROL; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; BONE; BONE DENSITY; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; DYSLIPIDEMIA; FEMALE; METABOLIC BONE DISEASE; ORGAN SIZE; OSTEOPOROSIS; OVARIECTOMY; RAT; UTERUS;

ASPIRIN; DIETHYLSTILBESTROL; DYSLIPIDEMIA; OSTEOPOROSIS; OVARIECTOMY; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOLOGICAL MARKERS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; DIETHYLSTILBESTROL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; ESTROGENS, NON-STEROIDAL; FEMALE; ORGAN SIZE; OVARIECTOMY; RATS; UTERUS;

MLCS; MLOWN;

EID: 84880228182     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.3967/0895-3988.2013.04.003     Document Type: Article

References (41)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet, 2011;377, 1276-87.
2. Liu Z, Piao J, Pang X, et al. The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China. J Bone Miner Metab, 2002;20, 181-9.
3. Ip TP, Leung J, Kung AW. Management of osteoporosis in patients hospitalized for hip fractures. Osteoporos Int, 2010;1, S605-14.
4. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs, 2011;71, 791-814.
5. Christel R, Samy S. Hormone therapy administration in postmenopausal women and risk of stroke. Womens Health (Lond Engl), 2011;7, 355-61.
6. de Paula FJ, Rosen G. Developing drugs to treat osteoporosis: lessons learned? Expert Opin Pharmacother, 2010;11, 867-9.
7. Yeh IT. Postmenopausal hormone replacement therapy: endometrial and breast effects. Adv Anat Pathol, 2007;14, 17-24.
8. Donna S. Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Womens Health (Lond Engl), 2011;7, 475-85.
9. Verheugt FW, Bolte AC. The role of aspirin in women's health. Int J Womens Health, 2011;3, 151-66.
10. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009;373, 1849-60.
11. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res, 2003;18, 1795-802.
12. Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk: study of osteoporotic fractures research group. J Bone Miner Res, 1996;11, 29-35.
13. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One, 2008;3, e2615.
14. Yu Q, Wu T, Cui L. Preventive effect of aspirin on cyclyphosphamide- induced bone loss in rats. The sixth Chinese Pharmaceutical Association Annual Meeting Proceedings. 2006. (In Chinese)
15. Yu Q, Wu T, Cui L. Effect of aspirin on cortical bone in cyclyphosphamide-treated rats. Chin Pharmacol Bull, 2011;27, 221-5. (In Chinese)
16. Chen ZW, Wu ZX, Sang HX, et al. Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model. Chin Med J, 2011;91, 925-9. (In Chinese)
17. Cui L, Wu T, Li QN, et al. Preventive effects of ginsenosides on osteopenia of rats induced by ovariectomy. Acta Pharmacol Sin, 2001;22, 428-34.
18. Cui L, Wu T, Liu YY, et al. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol Sin, 2004;25, 678-84.
19. nd edition). Pharmacological experimental methods. Beijing People's Medical Publishing House. (In Chinese)
20. Cui L, Wu T, Liu XQ, et al. Combination of ginsenosides with low dose estrogen showed synergetic effect on ovariectomy induced osteopenia in rats. Acta Pharmaceutica Sinica (Yao Xue Xue Bao). 2002;37, 501-5. (In Chinese)
21. Xu H, Wu T, Xu BL, et al. Effects of total flavonoids from dried fruits of cnidium monnieri on femora bone mineral density and bone biomechanical character of in ovariectomize rats. Model Med J China, 2009;11, 28-30. (In Chinese)
22. Xu BL, Wu T, Cui L, et al. The effects of diethylstilbestrol on different parts of the bone in ovariectomized rats. Chin J of Gerontology, 2004;12, 1173-6. (In Chinese)
23. Chow J, Tobias JH, Colston KW, et al. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest, 1992;89, 74-8.
24. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas, 2008;59, 2-6.
25. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA, 2002;287, 2668-76.
26. Gambacciani M, Ciaponi M, Cappagli B, et al. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. Maturitas, 2003;45, 175-83.
27. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med, 2000;133, 933-41.
28. Kaye AM, Weisman Y, Harell A, et al. Hormonal stimulation of bone cell proliferation. J Steroid Biochem Mol Biol, 1990;37, 431-5.
29. Somjen D, Weisman Y, Mor Z, et al. Regulation of proliferation of rat cartilage and bone by sex steroid hormones. J Steroid Biochem Mol Biol, 1991;40, 717-23.
30. Beato M. Gene regulation by steroid hormones. Cell, 1989;56, 335-44.
31. McDonnell DP, Vegeto E, Gleeson M A G. Nuclear hormone receptors as targets for new drug discovery. Biotechnology, 1993;11, 1256-61.
32. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med, 1997;186, 489-95.
33. Turner RT, Backup P, Sherman PJ, et al. Mechanism of action of estrogen on intramembranous bone formation: regulation of osteoblast differentiation and activity. Endocrinology, 1992;131, 883-9.
34. Coon D, Gulati A, Cowan C, et al. The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J Endod, 2007;33, 432-6.
35. Shi S, Yamaza T, Akiyama K. Is aspirin treatment an appropriate intervention to osteoporosis? Fut Rheumatol, 2008;3, 499-502.
36. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res, 2004;45, 1169-96.
37. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 2001;293, 1673-7.
38. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest, 2002;109, 1321-6.
39. van Diepen JA, Vroegrijk lO, Berbée JF, et al. Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Am J Physiol Endocrinol Metab, 2011;301, E1099-107.
40. Viswanathan AN, Feskanich D, Schernhammer ES, et al. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res, 2008;68, 2507-13.
41. Freek WA Verheugt, Antoinette C Bolte. The role of aspirin in women's health. International. J Women's Health, 2011;3, 151-66.